- Expansion Supports Rapid Development of Novel Drug Pipeline in
Oncology and Orphan Diseases -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2014--
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage
biopharmaceutical company developing novel therapeutics for orphan
patient populations with B-cell lymphomas and autoimmune diseases, today
announced the addition of three new management team members to support
the Company’s progress in its development pipeline. The Company has
appointed Kathryn Haviland, Vice President Rare Diseases; Joseph
Lobacki, General Manager of Oncology; and Walter Strapps, Ph.D.,
Executive Director of RNA Therapeutics.
“Kate, Joe and Walter will play a critical role as we continue to
advance and expand our pipeline of oncology and orphan therapeutics
derived from our proprietary nucleic acid technology platforms,” said
Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera
Pharmaceuticals. “Each of these individuals bring a breadth of
biopharmaceutical industry expertise in orphan disease product
development and global commercial strategy.”
Kathryn Haviland has joined the Company as Vice President Rare Diseases
and will be focusing on advancing Idera’s orphan autoimmune and rare
diseases programs through clinical development to commercialization. Ms.
Haviland joins Idera from Sarepta Therapeutics, where she served as Head
of Commercial Development and was responsible for strategic product
development and commercial planning of Sarepta’s lead investigational
product, eteplirsen, for the treatment of Duchenne muscular dystrophy.
As part of establishing a commercial plan at Sarepta, Ms. Haviland built
and maintained relationships with key opinion leaders and patient
advocacy groups and collaborated with the orphan disease community.
Prior to Sarepta, Ms. Haviland was Executive Director of Commercial
Development at PTC Therapeutics where she was responsible for
establishing and executing PTC’s commercial strategy and building its
corporate infrastructure. Before joining PTC, Ms. Haviland held
positions with increasing responsibilities at Genzyme. Ms. Haviland
holds a BA in Biochemistry/Molecular Biology and Economics from Wesleyan
University and an MBA from Harvard Business School.
Joseph Lobacki has joined Idera as General Manager of Oncology and is
charged with establishing Idera’s presence in the oncology community and
developing Idera’s oncology franchise. Mr. Lobacki previously served as
an independent consultant to multiple clinical-stage biopharmaceutical
companies providing guidance to research, clinical and regulatory groups
on lead programs in oncology and rare diseases and initiation of
commercial strategies. Prior to his consulting work, Mr. Lobacki was the
Senior Vice-President and Chief Commercial Officer at Micromet, Inc.
prior to its acquisition by Amgen, Inc. Prior to Micromet, Inc., Mr.
Lobacki held positions of increasing responsibility at several life
science companies, including serving as the Senior Vice President and
General Manager of the Transplant and Oncology business at Genzyme
Corporation, SangStat Medical Corporation, Cell Pathways, Inc.,
Rhone-Poulenc Rorer and Lederle Laboratories. Mr. Lobacki earned a BS in
Biology from Boston College and a BS in Pharmacy from the Massachusetts
College of Pharmacy. He holds several issued and pending patents for
novel therapeutic approaches to neoplastic diseases.
Walter Strapps, Ph.D., has joined Idera as Executive Director of RNA
Therapeutics and is responsible for building and advancing Idera's Gene
Silencing Oligoneucleotides (GSOs) research platform. Prior to Idera,
Dr. Strapps was the Director, RNAi Therapeutics at Merck & Co., Inc.
where he led siRNA lead identification and lead optimization efforts.
Dr. Strapps holds a B.Sc. in Biology from McGill University and an M.A.,
M.Phil and Ph.D. in Genetics and Development from Columbia University.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company
developing a novel therapeutic approach for the treatment of genetically
defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera’s
proprietary technology involves creating novel nucleic acid therapeutics
designed to inhibit over-activation of Toll-like Receptors (TLRs). In
addition to its TLR programs, Idera is developing gene silencing
oligonucleotides (GSOs) that it has created using its proprietary
technology to inhibit the production of disease-associated proteins by
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding the
Company’s strategy, future operations, collaborations, intellectual
property, cash resources, financial position, future revenues, projected
costs, prospects, plans, and objectives of management, are
forward-looking statements. The words “believes,” “anticipates,”
“estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,”
“potential,” “likely,” “projects,” “continue,” “will,” and “would” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking statements
and you should not place undue reliance on the Company’s forward-looking
statements. There are a number of important factors that could cause
Idera’s actual results to differ materially from those indicated or
implied by its forward-looking statements. Factors that may cause such a
difference include: whether results obtained in clinical trials such as
the results described in this release will be indicative of the results
that will be generated in future clinical trials, including in clinical
trials in different disease indications ; whether products based on
Idera’s technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the United
States Food and Drug Administration or equivalent foreign regulatory
agencies; whether, if the Company’s products receive approval, they will
be successfully distributed and marketed; and such other important
factors as are set forth under the caption “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended December 31,
2013. Although Idera may elect to do so at some point in the future, the
Company does not assume any obligation to update any forward-looking
statements and it disclaims any intention or obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
Investor Relations, Inc.
Sarah McCabe, 212-362-1200